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Fatigue is a predictable outcome of prolonged physical activity; yet its biological 
cause remains uncertain. During exercise, a polypeptide messenger molecule inter-
leukin-6 (IL-6) is actively produced. Previously, it has been demonstrated that admin-
istration of recombinant IL-6 (rhIL-6) impairs 10-km run performance and height-
ened sensation of fatigue in trained runners. Both high carbohydrate diets and 
carbohydrate ingestion during prolonged exercise have a blunting effect on IL-6 
levels postendurance exercise. We hypothesized that carbohydrate ingestion may 
improve performance during a prolonged bout of exercise as a consequence of a 
blunted IL-6 response. Seven recreationally trained fasted runners completed two 
90-min time trials under CHO supplemented and placebo conditions in a randomized 
order. The study was of a double-blinded, placebo-controlled, cross-over study 
design. Distance covered in 90 min was significantly greater following exogenous 
carbohydrate ingestion compared with the placebo trial (19.13 ± 1.7 km and 18.29 ± 
1.9 km, respectively, p = .0022). While postexercise IL-6 levels were significantly 
lower in the CHO trial compared with the placebo trial (5.3 ± 1.9 pg·mL−1 and 6.6 ± 
3.0 pg·mL−1, respectively; p = .0313), this difference was considered physiologically 
too small to mediate the improvement in time trial performance.
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Exercise fatigue has been described as the failure to continue exercising at a 
prescribed work rate1,2 in the presence of an increased subjective perception of 
effort.3 Most popular theories consider that fatigue develops as a result of specific 
biochemical changes in the active muscles4 although more recently the impor-
tance of central neural command is becoming apparent.5
It has been suggested that during exercise central command could be altered 
by changes in a circulating chemical.6 Indeed elevated plasma levels of the poly-
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peptide messenger molecule interleukin-6 (IL-6) have been associated with 
increased sensation of fatigue at rest7 and during exercise, resulting in a signifi-
cant impairment of 10-km run time trial performance in trained runners.8 IL-6 is 
actively produced within contracting skeletal muscles9 and the central nervous 
system (CNS)10 as well as peritendinous tissue11 and during prolonged exercise 
plasma IL-6 concentrations consistently increase (for review see Suzuki et al12) 
with levels increasing >100-fold postexercise.13 Importantly, IL-6 can cross the 
blood–brain barrier or act at the level of circumventricular organ outside of the 
blood brain barrier.14 Furthermore, IL-6 receptors exist at numerous sites in the 
brain. As previously hypothesized, IL-6 may be taken up by the brain during exer-
cise and the increased release of IL-6 from skeletal muscle during prolonged exer-
cise acts as a feedback mechanism contributing to the development of central 
fatigue.6
It appears that plasma IL-6 response to exercise is attenuated by carbohydrate 
ingestion15–17 and by high carbohydrate diets before exercise.18 This has led to the 
proposal that IL-6 acts in the manner of an exercise-induced glucose-regulating 
hormone and is released from either the muscle19 or the liver17 to maintain glyce-
mic homeostasis.17 Studies have investigated the effect of carbohydrate ingestion 
on IL-6 kinetics during fixed intensity exercise for a fixed duration15–17 and have 
reported a blunted IL-6 response and a reduced perception of effort.15 However, 
the effect of carbohydrate supplementation on the IL-6 response to exercise during 
self-paced athletic performance has not yet been evaluated.
Therefore, the purpose of this study was to determine whether carbohydrate 
ingestion (with the intention of reducing plasma levels of IL-6) during a 90-min 
self-paced time trial resulted in improved athletic performance.
Methods
Subjects
Seven healthy, recreationally trained male runners (mean ± SD age 24 ± 4 years, 
mass 74 ± 7 kg, height 178.8 ± 6.5 cm) volunteered for the study. All subjects 
completed an exercise challenge, which consisted of a 90-min time trial on a 
motorized treadmill, on two occasions in a randomized order (by laboratory tech-
nician who was not involved in the study) and the different treatment conditions 
each separated by one week. The trials took place in the exercise physiology labo-
ratory at the University of Portsmouth. Approval for this study was obtained from 
the University of Portsmouth Ethics Committee. Before participation in the trial, 
all subjects completed informed consent forms and a health questionnaire. Sub-
jects were excluded if they had a history of autoimmune, cardiovascular, endo-
crine or hematopoietic diseases.
Protocol
Self-Paced Time Trial. All subjects had prior experience of treadmill running 
and in the week before the trials completed a familiarization 90-min time trial. 
Trials were conducted at the same time in the morning following an overnight 
fast. A coefficient of variation of 0.94% for distance covered during 90-min time 
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trial has been reported for this test (personal communication with M. Barwood, 
University of Portsmouth). On each trial occasion, subjects reported to the labora-
tory at precisely the same time of day following an overnight fast. To standardize 
procedures, subjects were instructed to keep an accurate diary of their exercise 
training and dietary intake in the week before the first exercise trial, so that they 
could replicate these factors in the week before the second exercise trial. The 
study adopted a double-blind, placebo-controlled, cross-over design. Subjects 
were asked to refrain from heavy exercise in the 72-h period and any exercise in 
the 24-h period preceding each exercise trial.
Intervention. Following a preexercise blood sample, subjects consumed a fluid 
bolus (8 mL·kg−1 body mass) containing either maltodextrin (8%; CHO) or a pla-
cebo (PLA). PLA and CHO beverages were taste-matched by the addition of 
equal volumes of a lemon flavored sugar-free drink. Within 5 min of consuming 
the prescribed beverages, subjects began a 90-min self-paced time trial on a 
motorized treadmill. During each time trial, subjects ingested a beverage of either 
PLA or CHO (2 mL·kg−1 body mass) every 20 min. Neither the true composition 
of the beverage nor distance completed during each time trial was disclosed to the 
subjects until completion of both trials. Subjects were provided with elapsed time 
but not distance feedback. Heart rate, distance and rating of perceived exertion 
(RPE)20 were taken every 10 min during each 90-min time trial.
Blood Sampling and Analysis. Venous blood samples were drawn from the 
antecubital vein before and immediately following each time trial. Blood was col-
lected into appropriate Vacutainer tubes (Becton Dickinson, New Jersey, USA) 
and centrifuged at 1500  g for 10 min in a refrigerated centrifuge at 4°C. The 
supernatant was transferred into Eppendorf tubes and immediately frozen at 
−80°C until later analysis. Plasma IL-6 concentrations were analyzed from tripo-
tassium ethylene diamine tetraacetic acid–treated blood using an enzyme linked 
immunosorbent assay (IMMULITE, DPC, UK). Plasma glucose and lactate were 
measured on a BIOSEN C (EKF Diagnostic GmbH, West Germany) analyzer.
Data Analysis
Statistical evaluation of the results that passed the Kolmogorov–Smirnov normal-
ity test was carried out using either repeated measures ANOVA or paired Student’s 
t tests. When significance was identified with the repeated-measures ANOVA, a 
Tukey–Kramer multiple comparisons post hoc test was performed to determine 
the minimum significant difference (MSD). The q-value from each pairwise com-
parison was compared against the MSD to determine significance. Non-Gaussian 
distributed data were analyzed with a Wilcoxon matched pairs test. All statistics 
were performed on Graphpad Instat v 3.06. The accepted level of significance was 
P < .05.
Results
Carbohydrate ingestion in a fasted state significantly improved self-paced 90-min 
time trial running performance compared with the placebo ingestion (19.13 ± 1.7 
km and 18.29 ± 1.9 km, respectively, Student’s t test, p = .0022); all seven subjects 
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completed a greater distance in the CHO time trial than during the PLA time trial 
(Figure 1).
Preexercise IL-6 values were <2 pg·mL−1, which is below the detection limit 
of the ELISA. Therefore we examined differences between postexercise IL-6 con-
centrations using both repeated-measures ANOVA (where preexercise levels were 
assumed to be 2 pg·mL−1) and a Wilcoxon test comparing only the postexercise 
plasma IL-6 levels. The ANOVA found no significant differences in postexercise 
IL-6 between conditions (MSD = 3.997; q-value = 2.366; p > .05); however, the 
Wilcoxon test identified a statistically significant attenuation in the IL-6 response 
in CHO compared with PLA (5.3 ± 1.9 pg·mL−1 vs. 6.6 ± 3.0 pg·mL−1, respec-
tively; p < .0313).
Preexercise plasma glucose concentrations were similar between trials (MSD 
= 3.997; q-value = 0.175; p > .05); however, postexercise plasma glucose levels 
were significantly higher in CHO compared with PLA (Table 1; MSD = 3.997; 
q-value = 6.866; p < .001). Rating of perceived exertion, heart rate (Figure 2) and 
plasma lactate (Table 1) were not different between trials although they did 
increase over the duration of the trials (p < .001).
On completion of the study three of the seven subjects correctly identified the 
trial in which they had ingested carbohydrate.
Figure 1 — Effect of CHO (solid bar) and placebo ingestion (clear bar) on total distance run in 90-
min time trial (individual subject data, n = 7; P = .0022).
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Table 1 Effect of 90-min time trial run following either carbohydrate 
or placebo ingestion on plasma IL-6, glucose and lactate 
concentrations. Data are mean ± SD, n = 7.
Preexercise Postexercise
IL-6 (pg·mL−1)†
 CHO n.d 5.3 ± 1.9**
 Placebo n.d 6.6 ± 3.0
Glucose (mmol·L−1)†
 CHO 4.7 ± 0.4 6.8 ± 0.8*
 Placebo 4.3 ± 1.4 5.5 ± 0.5
Lactate (mmol·L−1)†
 CHO 0.8 ± 0.2 3.7 ± 1.1
 Placebo 0.8 ± 0.4 3.3 ± 1.5
n.d. = IL-6 preexercise were below detectable limits of the ELISA (>2 pg·mL−1).
* (ANOVA, p < .001).
** (Wilcoxon test, p = .0313) CHO trial significantly different to placebo trial.
† (p < .0001) main effect of time.
Figure 2 — Effect of CHO (●) and placebo () ingestion on heart rate (solid lines) and rating of 
perceived exertion (broken lines) during 90-min time trial. Main effect of time (P < .001). Data are 
presented as mean ± SD, n = 7.
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Discussion
This is the first study to attempt to manipulate the IL-6 response and its effect on 
self-paced athletic performance. The main finding of this study was that exoge-
nous carbohydrate ingestion significantly improved 90-min time trial performance 
and this was associated with a lower IL-6 concentration compared with the pla-
cebo trial. Our hypothesis that CHO may improve athletic performance by attenu-
ating the IL-6 response to prolonged exercise could be accepted from a statistical 
standpoint however, it is doubtful that these small differences could mediate the 
improvement in athletic performance. Previously, it has been demonstrated that 
moderate IL-6 levels (14 to 21 pg·mL−1) can impair 10-km time trial performance8 
but postexercise levels of IL-6 in the current study were substantially lower than 
those observed by Robson-Ansley et al.8
It should be noted that the IL-6 response is augmented with increased exer-
cise intensity.21 Therefore the true extent of the difference in IL-6 between trials 
due to CHO ingestion in this study is partially masked by the increased running 
speed adopted by the subjects during the CHO trial ie, through different mecha-
nisms. It is possible that the IL-6 response in the experimental condition was both 
attenuated and augmented by the CHO and intensity, respectively, compared with 
the placebo trial. Unfortunately we were unable to report the actual magnitude of 
IL-6 response from baseline to postexercise due to the sensitivity of the IL-6 
ELISA kit employed for analysis (minimum detection level >2 pg·mL−1). Future 
studies should endeavor to use high sensitivity commercially available ELISA kits 
with minimum detection limits <0.8 pg·mL−1). Nevertheless, our finding that 
plasma IL-6 concentration was greater in the PLA trial compared with the CHO 
trial is in agreement with other studies.15–17
There are two possible mechanisms that could explain the attenuation in IL-6 
release during the CHO trial. Firstly, a fall in intramuscular muscle glycogen 
stores could stimulate IL-6 release from the working muscle.22 Due to the fasted 
state of the subjects before the exercise trials, liver glycogen stores would likely 
be compromised and therefore only minimally be able to contribute to the main-
tenance of glucose homeostasis. Hence during the PLA trial intramuscular glyco-
gen would be the main source of substrate during exercise.23 However, during the 
CHO trial the ingestion of exogenous glucose, which then enters the circulation, 
may reduce the use of intramuscular glycogen and attenuate the release of IL-6 
from the muscle. Secondly, the increased IL-6 during exercise in the placebo trial 
was likely to be largely hepatic in origin as proposed by Starkie et al.17 Hepatic 
IL-6 appears to have a regulatory function in maintaining blood glucose homeo-
stasis during exercise. Before the release of hepatic IL-6 into the circulation, 
muscle derived IL-6 can partly mediate the hepatic glucose output by directly 
acting on hepatocytes to increase hepatic glucose release when blood glucose 
levels are compromised.24
We favor the latter mechanism to explain the results observed in this study 
based upon the effect that exogenous glucose ingestion has upon intramuscular 
and hepatic glycogen kinetics. The rate of glycolysis in the muscle is not altered by 
exogenous glucose supplementation during exercise durations less than 120 min,25 
whereas exogenous CHO ingestion can, at least partially, replace the liver as the 
source of blood glucose. Therefore, since euglycemia was maintained during both 
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trials the attenuated plasma IL-6 concentration in the presence of exogenous CHO 
may be a consequence of the reduced role of hepatic regulation in the maintenance 
of blood glucose homeostasis. Starkie et al17 reported that following 60 min of 
moderate intensity exercise, plasma IL-6 was significantly higher under placebo 
conditions in comparison with CHO supplemented trial but skeletal muscle IL-6 
mRNA was no different between trials suggesting skeletal muscle IL-6 release was 
unchanged. Hence, CHO ingestion may have blunted hepatic production of IL-6 
during exercise resulting in lower IL-6 levels following the CHO trial.
Even though subjects completed a greater distance during the CHO trial their 
RPE was similar between trials indicating that subjects were able to exercise at a 
higher intensity for the same perceived exertion. Previously, increased RPE has 
been associated with an increasing state of hypoglycemia during prolonged exer-
cise.26 However, Nehlsen-Cannarella et al15 found RPE was significantly higher 
when IL-6 concentrations were augmented despite euglycemia being maintained. 
This role of IL-6 in moderating perception of effort is further supported by 
research in which administered IL-6 impaired 10-km time trial performance but 
had no effect on RPE.8 The authors of that study concluded that elevated IL-6 may 
have activated serotonergic pathways.
The exact mechanism explaining the improved performance during the CHO 
exercise trial is not clear but may be linked to an increase in central drive or moti-
vation rather than cytokine or metabolic mediation. It is unlikely that 90-min time 
trial performance would be limited by endogenous glucose availability although 
subjects may have compromised liver glycogen as they were in a fasted condition 
before exercise.27 Carter et al28 suggest that CHO receptors in the oral cavity may 
modulate central pathways associated with motivation and improve athletic per-
formance when metabolic mediation is not a factor.
The IL-6 response to exercise is sensitive to both exercise intensity and dura-
tion but the single most important factor determining the magnitude of IL-6 eleva-
tion is exercise duration.29 Due to the study design we were unable to determine 
whether the magnitude of the attenuated IL-6 response as a consequence of the 
CHO ingestion was sufficient to explain the improved performance observed in 
the time trials. We suggest that future studies intending to test the hypothesis that 
attenuation of the IL-6 response to exercise improves athletic performance should 
use a preload protocol followed by a time trial (as described elsewhere30) to eluci-
date the separate effects of an intervention such as CHO ingestion on IL-6 kinetics 
and the effect of IL-6 release on exercise performance. The consequence of atten-
uating IL-6 production on athletic performance and fatigue during prolonged 
exercise is unknown and awaits further investigation.
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